Harmony Biosciences’ $270 Million Equity Financing

Cooley advised HBM Healthcare Investments and certain other investors on their lead investment in Harmony Biosciences’ completed $270 million equity financing.

Harmony used the proceeds of the funding to acquire exclusive US rights from French company Bioproject to develop, register and market pitolisant – a drug approved by the EU for the treatment of narcolepsy. Cooley partner Mehdi Khodadad led the team advising HBM.

Headquartered in Plymouth Meeting, Pennsylvania, Harmony is dedicated to developing innovative therapies to help patients with unmet medical needs. Harmony focuses on providing novel treatment options to patients with orphan and rare conditions, with an emphasis on central nervous system disorders.

HBM Healthcare Investments actively invests in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas with a track-record of more than 100 biopharma and healthcare investments that have resulted in significant value creation via sale transactions and IPOs since inception.

Cooley advised with a team including Mehdi Khodadad, Glen Sato (Picture), Natasha Leskovsek, Daniel Elefant, Nik Talreja, Dean Farmer, Pratusha Erraballi, Larry Teague, Kristy Brady, Serge Banini and Kehinde Ajayi.

Involved fees earner: Mehdi Khodadad – Cooley LLP; Glen Sato – Cooley LLP; Daniel Elefant – Cooley LLP; Nik Talreja – Cooley LLP; Pratusha Erraballi – Cooley LLP; Natasha Leskovsek – Cooley LLP; Dean Farmer – Cooley LLP; Kristy Brady – Cooley LLP; Larry Teague – Cooley LLP; Serge Banini – Cooley LLP; Kehinde Ajayi – Cooley LLP;

Law Firms: Cooley LLP;

Clients: HBM Healthcare Investments;

Print Friendly, PDF & Email

Author: Ambrogio Visconti